Log in to search using one of your social media accounts:

 

International trial confirms safety, effectiveness of HDR brachytherapy for cervical cancer
(American Society for Radiation Oncology) Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gray (Gy) each than following two, 9-Gy fractions of high-dose-rate (HDR) brachytherapy, but neither overall survival nor severe treatment-related side effects differed between the treatment groups. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news

Breast cancer patients largely find radiation therapy experience better than expected
(American Society for Radiation Oncology) A new survey finds breast cancer patients' actual radiation therapy experiences largely exceeded their expectations. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 25, 2017 Category: International Medicine & Public Health Source Type: news

Post-mastectomy Radiotherapy Affects Outcomes of Breast Reconstruction Post-mastectomy Radiotherapy Affects Outcomes of Breast Reconstruction
For women who have radiation therapy after mastectomy, autologous reconstruction is associated with a lower risk of complications and better satisfaction with outcome, compared with implant-based breast reconstruction.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Elekta and Brainlab Collaborate to Streamline Treatment Workflows for Stereotactic Radiation Therapy
Integration of Versa HD linear accelerator and ExacTrac empowers clinicians to optimize radiation therapy inside and outside the brain SAN DIEGO, September 22, 2017 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) and Brainlab have recon... Devices, Oncology, Neurosurgery Elekta, Brainlab, Versa HD, ExacTrac, stereotactic, radiosurgery, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 22, 2017 Category: Pharmaceuticals Source Type: news

Varian announces 1st patient treated with Halcyon
Radiation therapy firm Varian Medical Systems announced that a patient with...Read more on AuntMinnie.comRelated Reading: Varian updates treatment planning system Varian holds clinical workshop at Algerian facility Varian appoints new VP Varian inks deal with Bionix Varian treats 1st patient with HyperArc (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 21, 2017 Category: Radiology Source Type: news

New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

National Cancer Institute designates UCLA brain cancer program a site of research excellence
The brain cancer program at UCLA ’s Jonsson Comprehensive Cancer Center and the UCLA Brain Tumor Center has been designated a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute, making it one of only five brain cancer programs nationwide to receive this national recognition and substantial rese arch funding.The designation comes with an $11.4 million, five-year grant that recognizes UCLA ’s brain cancer program as one of the best in the country. The program supports research into the prevention, detection and treatment of one of the most lethal and deadly cancers, which often...
Source: UCLA Newsroom: Health Sciences - September 20, 2017 Category: Universities & Medical Training Source Type: news

Varian updates treatment planning system
Radiation therapy firm Varian Medical Systems has released its Eclipse 15.5...Read more on AuntMinnie.comRelated Reading: Varian holds clinical workshop at Algerian facility Varian appoints new VP Varian inks deal with Bionix Varian treats 1st patient with HyperArc Philips, Varian, IBA partner on Singapore cancer center (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 19, 2017 Category: Radiology Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Varian holds clinical workshop at Algerian facility
Radiation therapy firm Varian Medical Systems held its first education workshop...Read more on AuntMinnie.comRelated Reading: Varian appoints new VP Varian inks deal with Bionix Varian treats 1st patient with HyperArc Philips, Varian, IBA partner on Singapore cancer center FDA clears Varian's Halcyon rad therapy system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2017 Category: Radiology Source Type: news

Cancer drug stimulates tripolar mode of mitosis
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy. A current study has investigated the underlying mechanisms of this action - and which biomarkers may be useful for predicting the success of therapy. The study, published in the journal Oncogene, was carried out within the framework of the Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer at Helmholtz Zentrum M ü nchen and Munich University Hospital. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 12, 2017 Category: Biology Source Type: news

Radiation Oncology Institute's publication awards honor radiation oncology research
(American Society for Radiation Oncology) The Radiation Oncology Institute (ROI) announced today the winners of its inaugural publication awards, which recognize research on the value of radiation therapy for improving cancer outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 6, 2017 Category: Cancer & Oncology Source Type: news

Mesothelioma Patients Survive Longer with Trimodal Treatment
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - September 5, 2017 Category: Environmental Health Authors: Matt Mauney Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news

iCad wins Chinese approval for Xoft Axxent balloon applicators
iCad (NSDQ:ICAD) said today its Xoft Axxent balloon applicators have been cleared by the China Food & Drug Administration for treating early-stage breast cancer. The Nashua, N.H.-based company’s Xoft Axxent balloon applicators are part of its Xoft Axxent electronic brachytherapy system designed to perform intraoperative radiation therapy in early-stage breast cancer patients who meet specific selection criteria. The balloon applicator is used to deliver a single dose of radiation to the lumpectomy cavity to target cancer cells directly and limit exposure to health surrounding tissue, iCad said. “The Xo...
Source: Mass Device - August 30, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Women's Health iCad Inc. Source Type: news

Large study reveals women have superior response to esophageal cancer treatment
(Elsevier) Female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published online today in The Annals of Thoracic Surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 22, 2017 Category: International Medicine & Public Health Source Type: news

Nearly One-Third of Mesothelioma Patients Remain Untreated
A new report from the National Cancer Institute (NCI) shows between 20 and 30 percent of malignant mesothelioma patients do not receive any cancer treatment. The study, “Patterns of care and survival among patients with malignant mesothelioma in the United States,” published August 10 in the journal Lung Cancer, aimed to describe the patterns of care and subsequent survival among mesothelioma patients in the U.S. while adjusting for patient demographics and pre-existing health conditions. Using the NCI’s Surveillance, Epidemiology, and End Results (SEER) data, researchers discovered significant differenc...
Source: Asbestos and Mesothelioma News - August 21, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amount of mesothelioma patients eligible for surgery checkpoint inhibitors clinical trial enrollment cytoreduction surgery heated chemotherapy pleural mesothelioma heated intraperitoneal chemotherapy immunotherapy mesothelioma keytruda Lin Source Type: news

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: William C. Wood, MD Tags: Breast Cancer Oncology Journal Source Type: news

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Camille Berriochoa, MD Carisa Bohnak, BS Chirag Shah, MD Nicole Chahine, BS Tags: Breast Cancer Oncology Journal Source Type: news

7 medtech stories we missed this week: August 11, 2017
[Image from unsplash.com]From Xtant Medical’s 510(k) extension to Varian Medical’s distribution deal, here are seven medtech stories we missed this week but thought were still worth a mention. 1. FDA extends Xtant Medical’s 510(k) for Calix C spinal implant Xtant Medical announced in an Aug. 9 press release that the FDA has cleared its product line extensions for the Calix-C cervical inter body cages. The clearance allows for two larger footprints to be added for use with allograft. The Calix-C Cervical Interbody Spacer is designed for spinal fusion procedures at level one in patients who are skeletally m...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiovascular Clinical Trials Food & Drug Administration (FDA) Oncology Regulatory/Compliance Spinal Surgical Apifix Cardiac Science Hip Innovation Life Spine Inc. MedTech Pentax Medical Varian Medical Systems Xtant M Source Type: news

Antiperspirant Use Seems Safe During Breast Cancer Treatment: Study
Many doctors worry about skin damage during radiation, but new research found no such effect Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Radiation Therapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 11, 2017 Category: Consumer Health News Source Type: news

Antiperspirant Use Seems Safe During Breast Cancer Treatment: Study
FRIDAY, Aug. 11, 2017 -- Contrary to what some doctors might say, new research suggests it's OK to use antiperspirants while undergoing radiation therapy for breast cancer. Researchers surveyed 92 patients and found that 79 percent said their... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2017 Category: General Medicine Source Type: news

Varian inks deal with Bionix
Radiation therapy firm Varian Medical Systems has signed a distribution agreement...Read more on AuntMinnie.comRelated Reading: Varian treats 1st patient with HyperArc Philips, Varian, IBA partner on Singapore cancer center FDA clears Varian's Halcyon rad therapy system AccuBoost names U.S. distributor Bionix launches radiation therapy tattoo system Bionix adds Medspira's Breath Hold (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 9, 2017 Category: Radiology Source Type: news

Varian Medical Systems Signs Brachytherapy Applicator Distribution Agreement with Bionix Radiation Therapy
PALO ALTO, Calif., Aug. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement with Bionix® Radiation Therapy to distribute Bionix brachytherapy applicators. Varian will marke... Devices, Oncology, Distribution Varian Medical Systems, Bionix Radiation Therapy, brachytherapy applicators (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 9, 2017 Category: Pharmaceuticals Source Type: news

Moffitt Cancer Center and Cvergenx partner to personalize radiation therapy
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt's Radiation Oncology Department will utilize Cvergenx's Genomic-Adjusted Radiation Dose (GARD) model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

ViewRay sees Q2 sales grow, net loss narrows
Image-guided radiation therapy developer ViewRay announced a boost in revenues...Read more on AuntMinnie.comRelated Reading: ViewRay to highlight MRIdian Linac research at AAPM 1st patients treated with ViewRay's MRIdian system ViewRay sees drop in Q1 revenue ViewRay boosts borrowing capacity ViewRay lands FDA clearance for MRI linac (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 8, 2017 Category: Radiology Source Type: news

Promising Drug Reduces Growth of Aggressive Mesothelioma
Scientists in Italy have found a platinum-based drug that successfully lessens growth of the most aggressive type of mesothelioma cancer cells. Researchers at the University of Salento discovered the experimental drug Ptac2S was more effective in reducing the spread of sarcomatoid malignant pleural mesothelioma cells in mice compared to cisplatin — the most widely used chemotherapy drug for treating mesothelioma. Sarcomatoid is the least common of the three mesothelioma cell types but is considered more aggressive and harder to treat. A diagnosis with the sarcomatoid cell type is typically associated with a poor pro...
Source: Asbestos and Mesothelioma News - August 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alimta alternatives to cisplatin Antonella Muscella Biphasic mesothelioma chemotherapy for mesothelioma chemotherapy resistance DNA adducts epithelioid mesothelioma genomic activities mesothelioma clinical trials mesothelioma survival Source Type: news

Faced with many options, men with prostate cancer get help choosing the right treatments
Like many men diagnosed with prostate cancer, Bill Pickett faced a tough question when he came to UCLA for treatment: how to fight it?Prostate cancer is one of the more curable cancers — it has a 96 percent survival rate 15 years after diagnosis, according to the American Cancer Society. The options men have after a diagnosis have different side effects and trade-offs. So choosing, for example, between radiation therapy or surgery, can be complicated for a person.“When you’re diagnosed with prostate cancer, you realize that each treatment can have very different side effects,” said Pickett, who...
Source: UCLA Newsroom: Health Sciences - August 4, 2017 Category: Universities & Medical Training Source Type: news

Elekta MR-linac Consortium Brings Founding Members Together With Clinicians From Five New Centers to Highlight Progress
International experts collaborate to advance magnetic resonance radiation therapy (MR/RT) as a transformative approach to cancer care STOCKHOLM, August 3, 2017 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) announced today that five le... Devices, Oncology Elekta, Elekta MR-linac Consortium, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 3, 2017 Category: Pharmaceuticals Source Type: news

Accuray wins FDA nod for iDMS data management system
Accuray (NSDQ:ARAY)  said today it won FDA 510(k) clearance for its iDMS data management system designed for sharing data between the company’s treatment delivery platforms. The Sunnyvale, Calif.-based company said the iDMS system is designed to integrate data from its technology platforms, including the Radixact, TomoTherapy and CyberKnife systems, as well as the company’s Accuray Precision treatment planning and oncology information systems. The iDMS allows users to store and manage all patient and treatment data across multiple devices to allow for more informed, efficient radiation treatments, Acc...
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Software / IT Accuray Inc. Source Type: news

Elekta touts 21 studies at AAPM 2017
Radiation oncology vendor Elekta said its investigational Unity MR radiation...Read more on AuntMinnie.comRelated Reading: Elekta to install Bhutan's 1st linear accelerator Elekta begins installation of MR-linac system Elekta receives order from Ala. provider Elekta points to study of older lung cancer patients Elekta debuts MR-linac radiation therapy system at ESTRO (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 31, 2017 Category: Radiology Source Type: news

Founder of brain tumor program named Health Care Heroes Lifetime Achievement honoree
This year's Memphis Business Journal Health Care Heroes Lifetime Achievement winner spent 32 years at St. Jude Children's Research Hospital. Dr. Larry Kun joined St. Jude in 1984 to establish a department to treat cancer with radiation therapy and to initiate the hospital's multidisciplinary brain tumor program. The initiative eventually grew to become the largest pediatric brain tumor research program in the country. Before retiring last year, Kun served as St. Jude's clinical director and executive… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2017 Category: American Health Authors: Elle Perry Source Type: news

Boston Scientific warns on fluke S-ICD death
Boston Scientific (NYSE:BSX) last month alerted physicians after learning of a fluke incident involving its S-ICD pacemaker, in which a patient died when the device’s memory was corrupted by radiation. In a June letter to physicians, Marlborough, Mass.-based Boston Scientific wrote of “a single, isolated S-ICD event that resulted in a device-related patient death in May of this year.” “Boston Scientific engineers have determined that this patient’s S-ICD repeatedly delivered an atypical amount of energy (similar to the arrhythmia induction function) because a specific memory location was ...
Source: Mass Device - July 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Wall Street Beat Boston Scientific Cardiac Rhythm Management Source Type: news

Antiperspirant OK During Radiation Therapy Antiperspirant OK During Radiation Therapy
Most clinicians advise breast cancer patients who are undergoing radiation therapy to not use an antiperspirant, but a new study finds no scientific evidence to support this advice.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer
(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news

Elekta Introduces Advanced Cancer Treatment to Kingdom of Bhutan
THIMPHU, Bhutan, July 24, 2017 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) announced today that it has been chosen to deliver the first ever radiation therapy system to the Kingdom of Bhutan. The National Referral Hospital, the largest... Devices, Oncology Elekta, Elekta Compact, linear accelerator, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2017 Category: Pharmaceuticals Source Type: news

Breast cancer patients can use antiperspirants during radiotherapy
(University of Pennsylvania School of Medicine) Women undergoing daily radiation therapy for breast cancer are commonly told they should not use antiperspirant for fear that it could cause greater radiation damage to the skin, but a new study from the Perelman School of Medicine at the University of Pennsylvania showed there was no difference in the radiation skin dose absorbed by these patients with or without these deodorants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 24, 2017 Category: International Medicine & Public Health Source Type: news

ViewRay to highlight MRIdian Linac research at AAPM
Image-guided radiation therapy developer ViewRay plans to highlight 30 clinical...Read more on AuntMinnie.comRelated Reading: 1st patients treated with ViewRay's MRIdian system ViewRay sees drop in Q1 revenue ViewRay boosts borrowing capacity ViewRay lands FDA clearance for MRI linac ViewRay lands Japanese order (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 21, 2017 Category: Radiology Source Type: news

University Of Maryland School Of Medicine Scientist Receives Top Award for His Pioneering Work on Improving Radiation Therapy Outcome
Søren M. Bentzen, PhD, DMSc, a professor in the Department of Epidemiology and Public Health (EPH) at the University of Maryland School of Medicine (UM SOM), has been awarded a gold medal from the American Society for Radiation Oncology (ASTRO). This is the highest honor bestowed upon ASTRO members. It recognizes a distinguished scientist who has made major contributions to the field of radiation oncology. (Source: University of Maryland School of Medicine News Headlines)
Source: University of Maryland School of Medicine News Headlines - July 21, 2017 Category: Universities & Medical Training Source Type: news

Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc
Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy...
Source: Mass Device - July 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news

CU Boulder discovery could lead to better results for patients undergoing radiation
(University of Colorado at Boulder) A new study involving CU Boulder shows why some cells treated with radiation therapy for cancer leak chemical signals and damage unexposed healthy cells, findings that could lead to new medications that patients could take prior to radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2017 Category: Cancer & Oncology Source Type: news

Radiation prior to surgery reduces risk of secondary tumors in early-stage breast cancer
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt researchers found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2017 Category: Cancer & Oncology Source Type: news

The Role of Genomic Techniques in Predicting Response to Radiation Therapy
The understanding of the relationship between genetic variation and an individual patient ’s response to radiation therapy has gained significant ground over the past several years. Genetic markers have been identified that could ultimately serve as the foundation for predictive models in clinical practice, and that hold the potential to revolutionize the delivery of precision medicine in oncology. (Source: CancerNetwork)
Source: CancerNetwork - July 15, 2017 Category: Cancer & Oncology Authors: Nicholas G. Zaorsky, MD Noelle L. Williams, MD Robert B. Den, MD Shivank Garg, MD Tu Dan, MD Tags: Oncology Journal Radiation Oncology Review Article Source Type: news

American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
Proton beam therapy model policy recommends expanded access to advanced radiation therapy treatment for cancer patients ARLINGTON, Va., July 13, 2017 -- (Healthcare Sales & Marketing Network) -- The American Society for Radiation Oncology (ASTRO) has i... Devices, Oncology ASTRO , proton beam, proton therapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 13, 2017 Category: Pharmaceuticals Source Type: news

Radiotherapy boost based on PET not always helpful
Selectively increasing radiotherapy dose in tumor areas with significant uptake...Read more on AuntMinnie.comRelated Reading: Brain PET enhances radiation therapy planning Radiotherapy exploits advances in diagnostic imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 13, 2017 Category: Radiology Source Type: news

Right-Sided Metastatic CRC Benefits From Adding SIRT to Chemotherapy
Patients with colorectal cancer that has metastasized to the liver derive a significant benefit from selective internal radiation therapy (SIRT) combined with chemotherapy if their primary tumor is a right-sided tumor, but not if it is a left-sided primary tumor. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

Medical News Today: Colorectal cancer: Adding SIRT to chemotherapy boosts survival
For patients with advanced colorectal cancer, new research suggests that adding selective internal radiation therapy to chemotherapy may prolong survival. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 7, 2017 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

FDA requests more info on IsoRay ’ s GammaTile
IsoRay (NYSE:ISR) said today that the FDA requested additional data on the company’s pending 510(k) application for its GammaTile radiation therapy system. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. “This is a good outcome for the novel GammaTile product. With the completion of additional testing anticipated by the end of 2017, we project potential 510(k) clearance of the GammaTile product in the 1st half of 2018 which would all...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology IsoRay Source Type: news

A Rockville biotech could be the latest Md. firm to go public
The company said it needs the funding for clinical trials of two radiation therapy drugs. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 5, 2017 Category: Pharmaceuticals Authors: Andrea Cwieka Source Type: news

A Rockville biotech could be the latest D.C.-area firm to go public
The company said it needs the funding for clinical trials of two radiation therapy drugs. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 5, 2017 Category: American Health Authors: Andrea Cwieka Source Type: news